JAZZ PHARMACEUTICALS PLC's ticker is JAZZ and the CUSIP is G50871105. A total of 444 filers reported holding JAZZ PHARMACEUTICALS PLC in Q2 2024. The put-call ratio across all filers is 0.98 and the average weighting 0.2%.
About JAZZ PHARMACEUTICALS PLC
Jazz Pharmaceuticals plc is a biopharmaceutical company that specializes in developing and commercializing medicines for patients with serious medical conditions. The company's portfolio includes products for the treatment of sleep disorders, oncology, and hematology.
One of Jazz Pharmaceuticals' most successful products is Xyrem, a medication used to treat narcolepsy. Xyrem has been approved by the FDA since 2002 and has been a significant revenue generator for the company. In addition to Xyrem, Jazz Pharmaceuticals has a number of other products in its pipeline, including treatments for Parkinson's disease and epilepsy.
Jazz Pharmaceuticals has a strong leadership team, including CEO Bruce Cozadd and COO Daniel Swisher. The company has a market capitalization of over $8 billion and has consistently delivered strong financial results. In 2020, Jazz Pharmaceuticals reported revenue of $2.3 billion, an increase of 10% compared to the previous year.
Despite the challenges posed by the COVID-19 pandemic, Jazz Pharmaceuticals has continued to invest in research and development. The company recently announced positive results from a Phase 3 clinical trial of its treatment for acute lymphoblastic leukemia, which could potentially become a significant revenue driver in the future.
Overall, Jazz Pharmaceuticals is a well-respected company in the biopharmaceutical industry with a strong track record of success. With a robust pipeline of products and a talented leadership team, the company is well-positioned for continued growth in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2021 | $479,000 | -27.9% | 3,677 | -1.6% | 0.00% | -33.3% |
| Q2 2021 | $664,000 | +8.1% | 3,738 | +0.1% | 0.01% | 0.0% |
| Q1 2021 | $614,000 | -7.0% | 3,735 | -6.6% | 0.01% | 0.0% |
| Q4 2020 | $660,000 | +14.8% | 3,998 | -0.9% | 0.01% | 0.0% |
| Q3 2020 | $575,000 | -23.5% | 4,034 | -40.8% | 0.01% | -33.3% |
| Q2 2020 | $752,000 | -98.6% | 6,818 | -98.8% | 0.01% | -98.9% |
| Q1 2020 | $55,014,000 | -32.4% | 551,579 | +1.1% | 0.84% | -15.4% |
| Q4 2019 | $81,436,000 | +17.6% | 545,527 | +0.9% | 0.99% | +11.1% |
| Q3 2019 | $69,260,000 | -8.7% | 540,506 | +1.6% | 0.89% | -7.4% |
| Q2 2019 | $75,873,000 | -0.7% | 532,217 | -0.4% | 0.96% | -3.6% |
| Q1 2019 | $76,374,000 | +31.3% | 534,269 | +13.8% | 1.00% | +14.2% |
| Q4 2018 | $58,179,000 | -31.2% | 469,338 | -6.7% | 0.88% | -20.0% |
| Q3 2018 | $84,573,000 | -3.1% | 503,023 | -0.7% | 1.09% | -8.9% |
| Q2 2018 | $87,276,000 | – | 506,535 | – | 1.20% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Polaris Capital Management, LLC | 1,253,360 | $199,672,782 | 6.95% |
| Deep Track Capital, LP | 873,553 | $139,165,728 | 5.84% |
| GREAT POINT PARTNERS LLC | 160,000 | $25,489,600 | 5.00% |
| RK Capital | 129,185 | $20,580,462 | 4.88% |
| Nepsis Inc. | 82,606 | $13,159,962 | 4.41% |
| Fairbanks Capital Management, Inc. | 22,359 | $3,562,012 | 3.16% |
| AdvisorShares Investments LLC | 59,237 | $9,437,046 | 2.66% |
| Avidity Partners Management LP | 727,541 | $115,904,557 | 2.51% |
| F/M Investments LLC | 12,580 | $2,004,120 | 2.43% |
| Rhenman & Partners Asset Management AB | 128,000 | $20,391,680 | 2.13% |